Clinical trial update: Implications and management of residual disease after neoadjuvant therapy for breast cancer

Breast Cancer Research

Volumn 9, Issue 5, 2007, Pages

  Mayer, Erica L ^a   Carey, Lisa A ^b   Burstein, Harold J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CLINICAL TRIAL; EDITORIAL; FEMALE; HUMAN; MINIMAL RESIDUAL DISEASE; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PROGNOSIS;

EID: 40449139089     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1755     Document Type: Note

References (26)

1. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist 2006, 11:574-589. 10.1634/theoncologist.11-6-574, 16794237.
2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCilis A, Robidoux A, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16:2672-2685.
3. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, 96-102.
4. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19:4224-4237.
5. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003, 21:4165-4174. 10.1200/JCO.2003.12.005, 14559892.
6. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidaux A, Margolese R, Kahlenberg MS, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006, 24:2019-2027. 10.1200/JCO.2005.04.1665, 16606972.
7. Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol 2007, 18:874-880. 10.1093/annonc/mdm008, 17293601.
8. Rouzier R, Pusztai L, Delone S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 2005, 23:8331-8339. 10.1200/JCO.2005.01.2898, 16293864.
9. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, Mariani G, Rodriguez J, Carcangiu M, Watson D, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23:7265-7277. 10.1200/JCO.2005.02.0818, 16145055.
10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geistler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
12. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Peisch R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 166244, 12829800, 10.1073/pnas.0932692100.
13. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanelli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685. 10.1158/1078-0432.CCR-04-2421, 16115903.
14. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13:2329-2334. 17438091, 10.1158/1078-0432.CCR-06-1109.
15. Symmans W, Peintinger F, Hatzis C, Kuere H, Valero V, Hannessy B, Green M, Singletary E, Hortobagyi GN, Pusztai L. A new measurement of residual cancer burden to predict survival after neoadjuvant chemotherapy. Proc Am Soc Clin Oncol 2006, 24:A536.
16. Paik S. Importance of obtaining tissue for research - a case study in NSABP B27. Presented at National Cancer Institute meeting 'Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions', Bethesda, MD, 26-27 March 2007
17. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonaz W, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 2006, 24:1940-1949. 10.1200/JCO.2005.02.6187, 16622270.
18. Thomas E, Holmes FA, Smith TL, Buzdar AU, Fyre DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol 2004, 22:2294-2302. 10.1200/JCO.2004.05.207, 15197190.
19. Ionta M, Atzori F, Scanu A, Scanni A, Cortesi E, Calluri A, Di Costanzo F, Maiorino L, Minerba L, Massidda B, et al. Induction and reinduction chemotherapy following standard treatment in stage IIIB breast cancer patients achieving less than pCR (
20. von Minckwitz G, Blohmer JU, Raab G, Lohr A, Gerber B, Heinrich G, Eidtmann H, Kaufmann M, Hilfrich J, Jackisch C, et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005, 16:56-63. 10.1093/annonc/mdi001, 15598939.
21. Hurwitz H, Fefrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
22. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. N Engl J Med 2006, 355:2542-2550. 10.1056/NEJMoa061884, 17167137.
23. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799. 10.1200/JCO.2005.05.098, 15681523.
24. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E, Shenkier T, Davidson N. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005, 94:S6.
25. Burstein H, Spigel D, Kindsvogel K, Parker L, Bunnell C, Partridge A, Come S, Ryan P, Gelman R, Winer E. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 2005, 94(Suppl 1):S6.
26. Mayer E, Miller K, Rugo H, Peppercorn J, Carey L, Ryabin N, Winer E, Burstein H. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. Proc Am Soc Clin Oncol 2006, 25:56.